UCB completes acquisition of Neurona Therapeutics in deal valued up to US $1.15 billion

United Community Banks, Inc.

United Community Banks, Inc.

UCB

0.00
  • UCB completed its acquisition of Neurona Therapeutics, adding rezanecel to its epilepsy portfolio.
  • Deal value up to USD 1.15 billion, including USD 650 million upfront, with up to USD 500 million tied to milestones.
  • Rezanecel is in Phase I/II studies for drug-resistant mesial temporal lobe epilepsy.
  • Transaction expands UCB into regenerative medicine, targeting disease-modifying therapies and cell therapies beyond symptomatic treatment.
  • UCB kept its 2026 outlook, projecting high single-digit to low double-digit revenue growth at constant exchange rates.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. UCB SA published the original content used to generate this news brief on June 02, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.